Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) had its price objective reduced by HC Wainwright from $60.00 to $40.00 in ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

BTIG analyst Justin Zelin lowered the firm’s price target on Jasper Therapeutics (JSPR) to $64 from $90 and keeps a Buy rating on the shares ...

Jane Street Group LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) during the third quarter, ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Jasper Therapeutics Inc (JSPR) stock saw a decline, ending the day at $6.99 which represents a decrease of $-10.72 or -60.53% from the prior close of $17.71. The stock opened at $8.74 and touched a ...

Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...

In this article, we are going to take a look at where Jasper Therapeutics, Inc. (NASDAQ:JSPR) stands against other best multibagger stocks. November has been an eventful month so far for the ...

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of ...